# ArriVent BioPharma Inc. (AVBP) fundamentals

Data as of 2026-09-08. NASDAQ, United States. Sector: Healthcare / Biotechnology. Price $30.95, market value $1.5 billion.

## Valuation
- **P/E (trailing): n/a** (negative earnings). ArriVent BioPharma Inc. reported negative earnings over the last twelve months, so the P/E is not meaningful; use price-to-sales, EV/EBITDA and free-cash-flow yield instead.
- **Price / book: 4.1×**. The shares trade at 4.1× book value; book value is a meaningful part of the valuation.

## Profitability
- **Return on equity: -54.1%**. Return on equity is negative because earnings are negative.

## Growth
- **EPS growth (1 yr): -68.8%**. Earnings per share fell 68.8%.

## Financial health
- **Current ratio: 12.83** (quick 12.83). Current assets cover the next year's liabilities 12.83 times.
- **Piotroski F-score: 1/9**. 1 of 9 checks pass: weak or deteriorating financials.

## Dividends
- **Dividend: none**. ArriVent BioPharma Inc. does not currently pay a dividend.

## Analyst view
- **Analyst consensus: strong_buy** (10 analysts). 10 analysts cover ArriVent BioPharma Inc.; the consensus is strong_buy, with an average price target of $44.70 (+44% from the current price). Analyst opinion is shown for context; it is not part of the Fundamental Score.

## Price and momentum
- **Total return (1 yr): 58.6%** (YTD 53.8%, 3-mo 2.0%). The shares are up 58.6% over twelve months including dividends.
- **From 52-week high: -13.6%** (82.1% above the low). Trading 14% below its 52-week high.
- **200-day average: above**. The price sits above its 200-day moving average, the usual definition of an uptrend.
- **RSI (14-day): 53**. An RSI of 53 is neutral.
- **Beta (1 yr): 1.13** (volatility 58%). Beta of 1.13 against the S&P 500: the shares move roughly with the market.

Live score and charts: https://foliofundamentals.com/analyzer?s=AVBP · Page: https://foliofundamentals.com/stocks/avbp

Not investment advice.